Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the drug Deucravacitinib and its long-term safety and efficacy in psoriasis patients, while a new registry identifier has been added.SummaryDifference4%
- Check28 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check92 days agoChange DetectedThe website has updated to revision v2.14.2, noting that some NLM-NCBI services are experiencing heavy traffic, which may impact performance and availability.SummaryDifference0.9%
Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.